The Association of the British Pharmaceutical Industry (ABPI) have issued a statement regarding its application for judicial review versus The National Institute for Health and Care Excellence (NICE).
Following confirmation from the Administrative Court that The ABPI's application for judicial review has been turned down, the following statement has been issued.
"The ABPI is disappointed that the judicial review application has been turned down. It’s now appropriate for us to take time to reflect on the judgement with our members and decide next steps.”
For further information see 'ABPI applies for Judicial Review over new procedures that restrict access to cost-effective medicines’, 10 July 2017.
## ENDS ##
ABPI Press OfficeEmail: firstname.lastname@example.orgTelephone: +44 (0)20 7747 7147Mobile: +44 (0)7843 525 553
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.